Abstract Objective To investigate the effect of bevacizumab in the treatment of children with optic pathway glioma (OPG). Methods A retrospective analysis was performed for the clinical data of 30 children with OPG who underwent chemotherapy. According to whether bevacizumab was used, they were divided into conventional chemotherapy (carboplatin, vincristine and etoposide) group with 12 children and combined chemotherapy (bevacizumab, carboplatin, vincristine and etoposide) group with 18 children. The children were followed up to 6 months after chemotherapy, and the two groups were compared in terms of visual acuity and tumor size before and after chemotherapy and adverse reactions during chemotherapy. Results The combined chemotherapy group had a significantly higher proportion of children achieving tumor regression than the conventional chemotherapy group (P < 0.05), while there were no significant differences between the two groups in the proportion of children with improved visual acuity or adverse reactions (P > 0.05). No chemotherapy-related death was observed in either group. Conclusions Bevacizumab combined with conventional chemotherapy can effectively reduce tumor size. Compared with conventional chemotherapy, such combination does not increase adverse reactions and can thus become a new direction for the treatment of OPG in children.
WU Wan-Shui,LIU Jing-Jing,SUN Yan-Ling et al. Effect of bevacizumab in treatment of children with optic pathway glioma[J]. CJCP, 2019, 21(12): 1193-1197.
WU Wan-Shui,LIU Jing-Jing,SUN Yan-Ling et al. Effect of bevacizumab in treatment of children with optic pathway glioma[J]. CJCP, 2019, 21(12): 1193-1197.
Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma:a canadian pediatric brain tumor consortium study[J]. J Clin Oncol, 2016, 34(29):3537-3543.
[6]
Avery RA, Hwang EI, Jakacki RI, et al. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab[J]. JAMA Ophthalmol, 2014, 132(1):111-114.
[7]
Aguilera D, Mazewski C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma:a multi-institutional experience[J]. Childs Nerv Syst, 2013, 29(4):589-596.
Hay JL, Atkinson TM, Reeve BB, et al. Cognitive interviewing of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Qual Life Res, 2014, 23(1):257-269.
[11]
Bergthold G, Bandopadhayay P, Bi WL, et al. Pediatric low-grade gliomas:how modern biology reshapes the clinical field[J]. Biochim Biophys Acta, 2014, 1845(2):294-307.
[12]
Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas[J]. J Neurosurg, 1997, 86(5):747-754.
[13]
Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence[J]. Eur J Cancer, 2010, 46(12):2253-2259.
[14]
Bradfield SM, Sandler E, Geller T, et al. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer[J]. Pediatr Blood Cancer, 2015, 62(6):1004-1010.
[15]
van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer:a systematic review[J]. Crit Rev Oncol Hematol, 2017, 114:114-130.
[16]
Yu DY, Dahl GV, Shames RS, et al. Weekly dosing of carboplatin increases risk of allergy in children[J]. J Pediatr Hematol Oncol, 2001, 23(6):349-352.
[17]
Rosca L, Robert-Boire V, Delisle JF, et al. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas[J]. Pediatr Blood Cancer, 2018, 65(11):e27351.
[18]
Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours[J]. Nat Rev Neurosci, 2007, 8(8):610-622.
[19]
Tamura R, Tanaka T, Miyake K, et al. Bevacizumab for malignant gliomas:current indications, mechanisms of action and resistance, and markers of response[J]. Brain Tumor Pathol, 2017, 34(2):62-77.
[20]
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma[J]. N Engl J Med, 2014,370(8):709-722.
[21]
Diaz RJ, Ali S, Qadir MG, et al. The role of bevacizumab in the treatment of glioblastoma[J]. J Neuro Oncol, 2017, 133(3):455-467.
